Drug intelligence / Profile preview

RLD2204

Development stage: Preclinical
Lead developer: Hanmi Pharmaceutical

Overview

RLD2204 is an investigational drug developed by Hanmi Company Limited. Its mechanism of action has not been disclosed or remains unknown in the public domain. There are no approved indications, and it has not received regulatory approval in any country. RLD2204 has been used as an active comparator in at least one clinical trial for gastric ulcer, where it was administered alongside HPP2201 as part of a combination therapy arm[3][4]. No adverse events or detailed pharmacological properties have been reported.

Beyond the preview

Go deeper on RLD2204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLD2204.

Explore the full profile